ADNI: Alzheimer's Disease Neuroimaging Initiative

This study has been completed.

Study NCT00106899 Information provided by Alzheimer's Disease Cooperative Study (ADCS)

First Received: March 31, 2005 Last Updated: January 18, 2012 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	June 2011
Primary Completion Date:	June 2011 (Final data collection date for primary outcome measure)

No publications provided by Alzheimer's Disease Cooperative Study (ADCS)

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Schneider LS, Insel PS, Weiner MW; Alzheimer's Disease Neuroimaging Initiative. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol. 2011 Jan;68(1):58-66.

Schneider LS, Kennedy RE, Cutter GR; Alzheimer’s Disease Neuroimaging Initiative. Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement. 2010 Sep;6(5):367-77.